| Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations (NCT03454919) | Peking University Cancer Hospital & Institute | 2018-03-30 |
| A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma (NCT03422445) | Peking University Cancer Hospital & Institute | 2018-01-08 |
| SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients (NCT03448549) | Peking University Cancer Hospital & Institute | 2018-01-01 |
| Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC (NCT03402464) | Peking University Cancer Hospital & Institute | 2018-01-01 |
| Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer (NCT03425058) | Peking University Cancer Hospital & Institute | 2017-11-22 |
| Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer (NCT03286920) | Peking University Cancer Hospital & Institute | 2017-09-20 |
| Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer (NCT03113851) | Peking University Cancer Hospital & Institute | 2017-08-14 |
| Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China (NCT03792529) | Peking University Cancer Hospital & Institute | 2017-07-20 |
| Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) (NCT03199989) | Peking University Cancer Hospital & Institute | 2017-06-01 |
| Drug Sensitivity Screening for Gastrointestinal Cancer (NCT04298489) | Peking University Cancer Hospital & Institute | 2017-05-01 |
| Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (NCT02867839) | Peking University Cancer Hospital & Institute | 2017-04-24 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma (NCT03051555) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma (NCT03051542) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma (NCT03051568) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma (NCT03051581) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics (NCT03237130) | Peking University Cancer Hospital & Institute | 2017-02-15 |
| The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules (NCT02937467) | Peking University Cancer Hospital & Institute | 2016-12-01 |
| Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma (NCT02931201) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma (NCT03095079) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer (NCT02942043) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma (NCT02928861) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer (NCT02864849) | Peking University Cancer Hospital & Institute | 2016-08-01 |
| Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment (NCT02860234) | Peking University Cancer Hospital & Institute | 2016-08-01 |
| Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) (NCT02878057) | Peking University Cancer Hospital & Institute | 2016-05-01 |
| A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST (NCT02776878) | Peking University Cancer Hospital & Institute | 2016-05-01 |
| Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma (NCT02850991) | Peking University Cancer Hospital & Institute | 2016-04-01 |
| Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (NCT03031444) | Peking University Cancer Hospital & Institute | 2016-01-01 |
| A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients (NCT02727309) | Peking University Cancer Hospital & Institute | 2015-10-01 |
| A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients (NCT02619058) | Peking University Cancer Hospital & Institute | 2015-10-01 |
| Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients (NCT02500810) | Peking University Cancer Hospital & Institute | 2015-07-01 |
| RSYR for Fatigue Reduction in Cancer Survivors (NCT03911921) | Peking University Cancer Hospital & Institute | 2015-06-01 |
| A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms (NCT02413437) | Peking University Cancer Hospital & Institute | 2015-04-01 |
| A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. (NCT02398552) | Peking University Cancer Hospital & Institute | 2015-03-01 |
| Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection (NCT02767375) | Peking University Cancer Hospital & Institute | 2015-02-01 |
| Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients (NCT02330783) | Peking University Cancer Hospital & Institute | 2014-12-01 |
| Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System (NCT02233205) | Peking University Cancer Hospital & Institute | 2014-10-01 |
| Blood Detection of EGFR Mutation For Iressa Treatment (NCT02282267) | Peking University Cancer Hospital & Institute | 2014-10-01 |
| Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) (NCT02179528) | Peking University Cancer Hospital & Institute | 2014-09-01 |
| Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro (NCT02226224) | Peking University Cancer Hospital & Institute | 2014-06-01 |
| The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma (NCT03143140) | Peking University Cancer Hospital & Institute | 2014-05-22 |
| Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer (NCT02464215) | Peking University Cancer Hospital & Institute | 2014-03-01 |
| HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma (NCT03435302) | Peking University Cancer Hospital & Institute | 2014-02-01 |
| Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma (NCT02023710) | Peking University Cancer Hospital & Institute | 2013-12-01 |
| Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study (NCT01960829) | Peking University Cancer Hospital & Institute | 2013-09-01 |
| DNA Methylation Biomarkers and Metastasis of Gastric Carcinoma (NCT02159339) | Peking University Cancer Hospital & Institute | 2012-12-01 |
| A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma (NCT01782508) | Peking University Cancer Hospital & Institute | 2012-08-01 |
| Compare the Aesthetic Effect of Different Thyroidectomies (NCT03239769) | Peking University Cancer Hospital & Institute | 2012-06-01 |
| Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer (NCT02724176) | Peking University Cancer Hospital & Institute | 2012-01-01 |
| Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients (NCT01395056) | Peking University Cancer Hospital & Institute | 2011-07-01 |
| Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma (NCT01762150) | Peking University Cancer Hospital & Institute | 2011-06-01 |
| Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion (NCT01256801) | Peking University Cancer Hospital & Institute | 2010-11-01 |
| Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC) (NCT01231022) | Peking University Cancer Hospital & Institute | 2010-08-01 |
| Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy (NCT01198301) | Peking University Cancer Hospital & Institute | 2010-08-01 |
| Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients (NCT01232062) | Peking University Cancer Hospital & Institute | 2010-08-01 |
| Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer (NCT01199393) | Peking University Cancer Hospital & Institute | 2010-08-01 |
| Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) (NCT01180153) | Peking University Cancer Hospital & Institute | 2010-08-01 |
| Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis (NCT01167049) | Peking University Cancer Hospital & Institute | 2009-08-01 |